Thermo Fisher Scientific Highlights Strong 2025 Performance and Growth Strategy in New Presentation
I'm PortAI, I can summarize articles.
Thermo Fisher Scientific Inc. presented its 2025 performance and growth strategy at the J.P. Morgan Healthcare Conference, reporting revenues of approximately $44 billion and an R&D investment of $1.4 billion. The company highlighted its leadership in innovative technologies and biopharma services, focusing on attractive end markets such as diagnostics and healthcare. Ongoing efforts to enhance productivity and customer engagement were also discussed. The full presentation is accessible via a provided link.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments